eISSN: 2450-5722
ISSN: 2450-5927
Journal of Health Inequalities
Current issue Archive About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
 
1/2019
vol. 5
 
Share:
Share:
more
 
 

The future of treatment of tobacco dependence – harnessing technology to deliver hybrid interventions

Aleksandra Herbeć

J Health Inequal 2019; 5 (1): 49
Online publish date: 2019/07/31
Article files
- The future.pdf  [0.05 MB]
- 16_Herbeć_slides.pdf  [1.16 MB]
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 
Over the past decades many high-income countries have witnessed marked declines in the prevalence of smoking among adults and children. This success could be attributed to several factors, including evidence-based tobacco control programmes, as well as supranational initiatives and grassroots movements, energised by the World Health Organization (WHO) Framework Convention on Tobacco Control (FCTC). Nonetheless, 1 billion people globally continue to smoke. While the majority of smokers want to quit and make frequent attempts to do so, stronger strategies are needed to increase abstinence rates.
There has been a growing offer in terms of on-prescription and over-the-counter pharmacotherapy supporting smoking cessation. More recently we have seen the emergence of next-generation diverse nicotine-delivery devices that might aid cessation, at least among some smokers. In countries like Poland we have also observed a rekindled interest among smokers in pharmacological support, which could at least partially be attributed to vigorous marketing and promotional campaigns, especially on television. Indeed, around one million packages of cessation medications were sold in Poland in 2014 and 2015, primary of cytisine-based drugs.
However, there are important limitations to the many cessation programmes. First of all, access to affordable and evidence-based cessation support is very limited in many countries, and only a small minority of smokers in Europe access such support. Secondly, adherence to both behavioural as well as pharmacological support is low, which is likely to hinder success.
Digital interventions have long held promise to offset some of the limitations of traditional cessation support, including to extend the reach of cessation programmes. We have evidence that many forms of self-help interventions can aid cessation, including printed materials, mobile-based support (e.g. SMS texting), as well as computer- and Internet-based support. More recently, interest has shifted towards smartphone-based programmes for quitting smoking that offer ever more diverse opportunities to intervene, collect data, and personalise the support offered. However, evidence on their effectiveness remains scarce, which is also due to the challenges of conducting well controlled studies in this field. Moreover, technologically-supported cessation programmes face two key challenges: low uptake among the general population, and high attrition and low engagement that may be insufficient to generate an effect.
Successful harnessing of technology to support smoking cessation is likely to require approaches that address the barriers to use and adherence to such programmes. They will also need to be accompanied by effective implementation strategies. This is especially important within healthcare systems, which engage and support vulnerable and priority populations of smokers that could benefit most from cessation in the immediate future.
Healthcare professionals can play a pivotal role in the delivery of evidence-based and technology-assisted cessation support to their patients and their families. A new programme, STAR (Smoking Treatment Advisory Resource), which will soon be available in Poland, has been developed to support hybrid interventions that can combine expert input by clinicians with digitallydelivered assistance. Research on such programmes is required to help determine how to best implement and develop them further.

DISCLOSURE

The author has received unrestricted funds as part of Global Bridges at Mayo Clinic and Pfizer Independent Grants for Learning and Change Request for Proposals: EUROPEAN PROGRAM to develop and evaluate programme STAR, and researches the use of technology in smoking cessation.
This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe